AVATAMED

21/07/2022

July is Sarcoma Awareness Month. Due to the rarity of the disease, Sarcoma is often known as the “forgotten cancer”.

References & resources:
1) National Cancer Assistance Foundation Inc. (NCAF): https://natcaf.org/blog/sarcoma-the-forgotten-cancer/
2) National Cancer Centre Singapore: https://www.nccs.com.sg/patient-care/conditions-treatments/sarcoma/overview
3) Parkway Cancer Centre: https://www.parkwaycancercentre.com/sg/learn-about-cancer/types-of-cancer/cancer-details/sarcoma
4) Sarcoma Alliance: https://sarcomaalliance.org/what-is-sarcoma/
5) Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/sarcoma/symptoms-causes/syc-20351048
6) National University Cancer Institute Singapore: https://www.ncis.com.sg/Cancer-Information/About-Cancer/Pages/Sarcoma.aspx

04/10/2021

AVATAMED will join our counterparts in ASEAN to present at the ASEAN NEXT 2021 Summit on 05 October 2021, organised by DOST Philippines.

We look forward to seeing you there!

23/07/2021

We are delighted to be selected as 1 of the 9 finalists at this year Tech Planter World Singapore Demo Day, organised by Leave a Nest Singapore.

Join us on 24 July (Saturday), from 12 noon at the Demo Day!

Details can be found at https://en.techplanter.com/2021/07/21/tpsg-demoday/

02/07/2021

Cancer treatments breakthroughs over the past 150+ years!

Credit: Icon Cancer Centre - Singapore

From surgery through to the latest in immunotherapy, learn more about the history of cancer treatment.

02/06/2021

Pleased to announce the setting up of Joint Service Lab with Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR).

Building on our relationship with IMCB, we hope to advance precision medicine and improve patient treatment outcome.

https://finance.yahoo.com/news/avatamed-sets-joint-lab-stars-010000026.html

AVATAMED (www.avatamed.com), a precision medicine service company based in Singapore, announced the setting up of a joint lab with Singapore's Institute of Molecular and Cell Biology (IMCB) at the Agency for Science, Technology and Research (A*STAR), to offer precision oncology services. Through thi...

01/02/2021

We are honoured to be selected by The Startup Pill as one of the top 101 Life Science Startups to look out for in 2021!



https://startupill.com/101-quality-life-science-startups-to-look-out-for-in-2021/

This article showcases Startup Pill’s top picks for the best Life Science startups. These startups are taking a variety of approaches to innovating inside of the Life Science industry and around the world. They are all exceptional startups well worth a follow. We tried to pick companies across the...

07/12/2020

Join us as we discuss about AVATAMED and how COVID-19 has affected and brought opportunities to AVATAMED and the MedTech industry @ Singapore Science Park & NUS Enterprise

https://www.innovationmadereal.sg/event/medtech-in-a-covid-19-world

30/10/2020

We are excited to collaborate with Macrogen, a global precision medicine Company with the best-in-class genetic platform, in offering our Precision Medicine services!

AVATAMED's drug screening technology (AVATASCAN), together with Macrogen's genetic platform, bring tremendous values to oncologists and their patients, as well as to the Pharmaceutical Industry.

SINGAPORE, Oct. 30, 2020 /PRNewswire/ -- AVATAMED (www.avatamed.com), a precision medicine service company based in Singapore, represented by CEO Mr. Hong Boon Toh, has entered into a business agreement on 29 October 2020 with Macrogen (www.macrogen.com), a biotechnology company in precision medicin...

29/10/2020

We are at K-Quarantine Expo 2020 in South Korea from 28 - 30 October to present some of our solutions for COVID-19 and infectious diseases. Check out our solutions at www.avatahealthcare.com!

02/10/2020

Proud to be featured as one of the promising in the Industry!

In recent years, the convergence of big data, artificial intelligence, and biotechnology has spurred a golden age of drug discovery. Today, the business of sequencing DNA and building scaffolds for synthetic DNA is as competitive

11/08/2020

We are pleased to announce the completion of our Seed Funding of US$1 million in March 2020.

We welcome Professor Pierce Chow, Senior Consultant at National Cancer Centre Singapore (NCCS), Professor Vinay Tergaonkar, Research Director at Institute of Molecular Cell Biology (IMCB) Singapore, Dr. Jae-Hoon Song, ex-President at Samsung Medical Centre, and Chung Joon, President at Solid Inc., as Board of Directors.

Please refer to news for more information on this Funding.
https://lnkd.in/djbPZU2

Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.

09/08/2020

We are pleased to annouce the signing of a Distribution Agreement with BioTNS. This Agreement allows AVATAMED to offer the COVID-19 RT-PCR PNA Diagnostic Kits worldwide, and adds to AVATAMED growing portfolio of infectious disease-related Healthcare products.

Please view the Press Releases:
http://www.sisanewszine.co.kr/news/articleView.html?idxno=11284
http://www.koreabiz.org/news/view.php?idx=26645&mcode=msub1

The molecular diagnostic kit developed by TNS is a reagent that amplifies and detects the amount of virus gene through reverse transcription polymerase chain reaction (RT-PCR), and has been approved for emergency use by the U.S. Food and Drug Administration (FDA). The biggest advantage of the COVID-19 PT-PCR PNA KIT is the improved sensitivity and precision by 2 to 5 times, compared to other diagnostic kits, resulting in very low false positives and false negatives.

Please visit www.avatahealthcare.com for more information.

05/08/2020

We are pleased to announce the signing of an overseas distributor contract for the the sales of NanoFocusRay Mobile CT Phion 2.0.

Please refer to press release:
http://www.newsa.co.kr/news/articleView.html?idxno=253132
http://www.hrdnews.org/news/articleView.html?idxno=4849

Phion 2.0 is a portable CT that can be installed and operated anywhere, providing for quick examinations in the field that can relieve patients' anxety. Radiation dosage is also one-fourth that of a normal CT, reducing the patient's radiation exposure burden.

Phion 2.0 was originally developed for musculoskeletal and spinal imaging, but due to the COVID-19 pandemic, it was also certified by the South Korean Ministry of Food and Drug Safety (MFDS) on 11 March 2020 for the diagnosis of COVID-19 patients.

Please visit www.avatahealthcare.com for more information.

04/08/2020

This pandemic, we want to be at the forefront in the fight against COVID-19. We do this by bringing quality products and devices to Healthcare professionals.

With this, we proudly launch our Avata Healthcare website.
www.avatahealthcare.com

Please join us in our effort.

14/07/2020

We are pleased to announce our partnership with CBmed GmbH in Europe on a Precision Cancer Project. Leveraging on AVATAMED's drug screening and genomic data analysis technology, the partnership will advance this joint effort to the rest of Europe through engagement with the oncology industry and pharmaceutical companies.

https://sg.news.yahoo.com/avatamed-partners-cbmed-europe-precision-071600493.html